GRIN2A and Alzheimer disease: According to findings by Hanson and colleagues in 2020, the use of GluN2A-selective positive allosteric modulators such as GNE-0723 led to a reduction in abnormal low-frequency oscillations and epileptiform discharges, while also demonstrating an improvement in cognitive deficits in a mouse model of Alzheimer’s disease [88].